Dark

Check out our API

ICPT
Intercept Pharmaceuticals, Inc.
stock NASDAQ

Inactive

Nov 7, 2023

19.00USD+0.211%(+0.04)3,963,455

Pre-market

0.00USD-100.000%(-18.96)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 11, 2022

10:11AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 11, 2022 Benzinga

04:43AM EST B. Riley Securities Upgrades Intercept Pharmaceuticals to Buy, Raises Price Target to $30 Benzinga

Jan 6, 2022

06:07PM EST Pomerantz Law Firm Announces the Filing of a Class Action against Intercept PR Newswire

Dec 20, 2021

08:03AM EST Intercept Pharmaceuticals Announces Top-line Data From Its Phase 3 REVERSE Trial Will Be Delayed From Our Previous Guidance Of Near The End Of The Year And Is Now Expected In The First Quarter Of 2022 Benzinga

08:00AM EST Intercept Pharmaceuticals, Inc.(NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that top-line data from its Phase 3 REVERSE trial will be delayed from our previous guidance of near the end of the year and is now expected in the first quarter of 2022. GlobeNewswire Inc

Dec 9, 2021

09:45PM EST Intercept Announces Withdrawal Of EMA Marketing Authorization Application For Obeticholic Acid For Advanced Liver Fibrosis Due To NASH Benzinga

07:00AM EST Intercept Announces Withdrawal of EMA Marketing Authorization GlobeNewswire Inc

Nov 15, 2021

11:23AM EST Intercept Posts Long-Term Data For Obeticholic Acid In Chronic Liver Disease Patients Benzinga

11:07AM EST Intercept Announces New Long-Term Data Demonstrating Potential Of Obeticholic Acid To Improve Transplant-Free Survival In Patients With PBC Benzinga

08:00AM EST Analysis compares findings from the long-term safety extension of the Phase 3 POISE trial to PBC natural history data from the Global PBC and UK-PBC databases GlobeNewswire Inc

Nov 11, 2021

08:01AM EST Intercept to Present at Upcoming Investor Conferences GlobeNewswire Inc

Nov 4, 2021

05:57AM EDT Raymond James Maintains Outperform on Intercept Pharmaceuticals, Raises Price Target to $44 Benzinga

Nov 3, 2021

09:19AM EDT The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering Benzinga

09:15AM EDT Intercept Pharmaceuticals Q3 EPS $(0.63) Beats $(1.09) Estimate, Sales $92.83M Beat $83.02M Estimate Benzinga

09:15AM EDT Intercept Pharmaceuticals Raises FY21 Worldwide Ocaliva Sales Guidance From $325M-$340M To $355M-$370M Vs. $339.04M Est. Benzinga

09:10AM EDT Earnings Scheduled For November 3, 2021 Benzinga

07:00AM EDT Worldwide Ocaliva net sales of $92.8 million, representing 17% growth over the prior year quarter GlobeNewswire Inc

Nov 2, 2021

10:54AM EDT Intercept Announces Late-Breaking Oral Presentation And Poster Presentations At The Liver Meeting Benzinga

08:00AM EDT Late-breaking oral presentation compares transplant-free survival in patients with PBC treated with OCA to external controls from the Global PBC and UK-PBC study groups GlobeNewswire Inc

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 27, 2021

08:00AM EDT Intercept to Announce Third Quarter 2021 Financial Results on GlobeNewswire Inc

Sep 21, 2021

08:00AM EDT Intercept to Present at the 2021 Cantor Virtual Global Healthcare GlobeNewswire Inc

Sep 13, 2021

08:00AM EDT Intercept Pharmaceuticals Announces Convertible Notes Repurchase GlobeNewswire Inc

Sep 1, 2021

08:00AM EDT Intercept to Present at the Virtual Baird 2021 Global Healthcare GlobeNewswire Inc

Aug 20, 2021

10:15AM EDT Intercept Pharmaceuticals, Inc. (ICPT) shares are sliding on Friday morning trade, continuing a bearish trend for the last several weeks. There were no corporate announcements from the company today to influence the stock movement. RTTNews

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 20, 2021 Benzinga

07:52AM EDT 10 Biggest Price Target Changes For Friday Benzinga

05:10AM EDT Goldman Sachs Downgrades Intercept Pharmaceuticals to Sell, Lowers Price Target to $10 Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 11, 2021

10:23AM EDT Shares of Intercept Pharmaceuticals Inc. (ICPT) slipped over 8% on Wednesday morning after the company announced convertible notes exchange, new issuance and stock repurchase. RTTNews

Aug 6, 2021

10:54AM EDT Return on Capital Employed Overview: Intercept Pharmaceuticals Benzinga

Aug 2, 2021

06:10AM EDT HC Wainwright & Co. Maintains Neutral on Intercept Pharmaceuticals, Lowers Price Target to $18 Benzinga

Jul 30, 2021

10:09AM EDT RBC Capital Maintains Sector Perform on Intercept Pharmaceuticals, Raises Price Target to $23 Benzinga

Jul 29, 2021

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

07:39AM EDT Intercept Pharmaceuticals: Q2 Earnings Insights Benzinga

07:19AM EDT Intercept Pharmaceuticals Reaffirms FY21 Ocaliva Net Sales Guidance Of $325M-$340M Benzinga

07:19AM EDT Intercept Pharmaceuticals Q2 EPS $(0.33) Beats $(1.21) Estimate, Sales $96.58M Beat $82.95M Estimate Benzinga

07:00AM EDT Worldwide Ocaliva net sales of $96.6 million, representing 25% growth over the prior year quarter GlobeNewswire Inc

04:23AM EDT Earnings Scheduled For July 29, 2021 Benzinga

Jul 28, 2021

10:43AM EDT Earnings Outlook For Intercept Pharmaceuticals Benzinga

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 20, 2021

12:48PM EDT Intercept Pharmaceuticals Granted U.S. Patent Titled 'Methods and intermediates for the preparation of bile acid derivatives' Benzinga

Jul 19, 2021

07:00AM EDT Intercept to Announce Second Quarter 2021 Financial Results on GlobeNewswire Inc

Jun 21, 2021

08:00AM EDT New analyses from the Phase 3 REGENERATE study highlight the relationship between early reductions of aminotransferases and fibrosis improvement in patients with fibrosis due to NASH treated with obeticholic acid (OCA) GlobeNewswire Inc

Jun 15, 2021

08:00AM EDT Intercept to Present at the Raymond James 2021 Human Health GlobeNewswire Inc

Jun 9, 2021

08:00AM EDT Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer. GlobeNewswire Inc

Jun 7, 2021

08:06AM EDT Intercept Appoints Andrew Saik As Chief Financial Officer Benzinga

08:00AM EDT Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Andrew Saik as Chief Financial Officer. GlobeNewswire Inc

May 27, 2021

08:24AM EDT The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs Benzinga

08:00AM EDT Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 11:30 a.m. ET. GlobeNewswire Inc

May 26, 2021

04:30PM EDT Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Ocaliva (obeticholic acid or OCA) Prescribing Information in the United States has been updated. GlobeNewswire Inc

02:24PM EDT FDA Restricts Use Of Intercept's Ocaliva In Liver Disease with Advanced Cirrhosis Citing Risk Of Serious Liver Injury Benzinga

01:31PM EDT UPDATE: Jefferies Says FDA Update To Intercept Label For Obeticholic Acid Was Inline with Expectations, Sees Update Negatively Impacting 10-20% Of Current Primary Biliary Cholangitis Market Benzinga

01:30PM EDT Intercept Shares At Session High As Traders Circulate Commentary From Jefferies The FDA Formally Updated Label For Co.'s Obeticholic Acid For Treatment Of Fibrosis Due To NASH Benzinga

12:13PM EDT B. Riley Securities Downgrades Intercept Pharmaceuticals to Neutral, Lowers Price Target to $18 Benzinga

07:33AM EDT The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing Benzinga

May 25, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021 Benzinga

08:55AM EDT B. Riley Securities Downgrades Intercept Pharmaceuticals to Neutral Benzinga

07:53AM EDT The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal Benzinga

May 24, 2021

06:39AM EDT NGM Biopharma to Release Mid-Stage NASH Data Monday: What to Expect? Benzinga

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

08:00AM EDT Intercept to Present at the 2021 RBC Capital Markets Global GlobeNewswire Inc

May 11, 2021

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

May 7, 2021

08:37AM EDT Goldman Sachs Maintains Neutral on Intercept Pharmaceuticals, Lowers Price Target to $18 Benzinga

08:21AM EDT Raymond James Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to $40 Benzinga

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

07:48AM EDT Intercept Pharmaceuticals Sees FY21 Ocaliva Sales $325M-$340M Benzinga

07:47AM EDT Intercept Pharmaceuticals Q1 EPS $(1.22) Beats $(1.44) Estimate, Sales $81.66M Beat $81.20M Estimate Benzinga

07:00AM EDT Worldwide Ocaliva net sales of $81.7M, representing 12% growth over the prior year quarter GlobeNewswire Inc

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

May 5, 2021

10:06AM EDT Earnings Preview: Intercept Pharmaceuticals Benzinga

Apr 26, 2021

08:00AM EDT Intercept to Announce First Quarter 2021 Financial Results on May GlobeNewswire Inc

Mar 12, 2021

06:30AM EST HC Wainwright & Co. Upgrades Intercept Pharmaceuticals to Neutral, Lowers Price Target to $21 Benzinga

Mar 10, 2021

08:06AM EST Intercept Reaffirms FY21 Guidance; NOTE: Co. In Feb. Guided FY21 Worldwide Ocaliva Net Sales $325M-$355M Benzinga

08:05AM EST Intercept Announces Departure Of Chief Financial Officer Sandip Kapadia; Rocco Venezia Appointed Chief Accounting Officer And Acting CFO Benzinga

08:01AM EST -- Rocco Venezia Appointed Chief Accounting Officer and Acting CFO - -- Intercept Reiterates 2021 Financial Guidance - GlobeNewswire Inc

Mar 4, 2021

08:12AM EST The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company Benzinga

Mar 2, 2021

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

08:00AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

07:11AM EST Needham Maintains Buy on Intercept Pharmaceuticals, Lowers Price Target to $34 Benzinga

Mar 1, 2021

11:41AM EST Wedbush Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to $88 Benzinga

Feb 26, 2021

08:17AM EST The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida Benzinga

08:14AM EST Raymond James Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to $52 Benzinga

Feb 25, 2021

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

07:23AM EST Intercept Pharmaceuticals Sees FY21 Worldwide Ocaliva Net Sales $325M-$355M Benzinga

07:22AM EST Intercept Pharmaceuticals Q4 EPS $(1.58) Misses $(1.47) Estimate, Sales $83.27M Miss $85.01M Estimate Benzinga

07:00AM EST Worldwide Ocaliva net sales of $83.3 million and $312.7 million for the fourth quarter and full year 2020, representing 18% and 25% growth over the prior year GlobeNewswire Inc

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 23, 2021

11:08AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 23, 2021 Benzinga

08:00AM EST Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Dagmar Rosa-Bjorkeson to its Board of Directors as of April 1, 2021. GlobeNewswire Inc

07:00AM EST HC Wainwright & Co. Downgrades Intercept Pharmaceuticals to Sell, Announces $25 Price Target Benzinga

Feb 19, 2021

08:00AM EST Intercept to Present at Upcoming Investor Conferences GlobeNewswire Inc

Feb 17, 2021

08:06AM EST Avadel Pharmaceuticals Appoints Richard Kim As CCO; Says He Will Lead Launch Of Once-Nightly FT218, Pending Regulatory Approval Benzinga

08:00AM EST Avadel Pharmaceuticals Appoints Richard Kim as Chief Commercial GlobeNewswire Inc

08:00AM EST Lisa DeFrancesco, Senior Vice President, Corporate Affairs & Investor Relations, will join Intercepts Executive Leadership Team GlobeNewswire Inc

Feb 11, 2021

08:00AM EST Intercept to Announce Fourth Quarter and Full Year 2020 Financial GlobeNewswire Inc

Jan 27, 2021

01:43PM EST Intercept Pharmaceuticals Says Analyst Note Commenting On Listong Of Co's Product On FDA Adverse Effect Reporting System Is 'Incorrect' Benzinga

01:35PM EST Intercept Company Statement on Analyst Note GlobeNewswire Inc

Jan 15, 2021

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 15, 2021 Benzinga

08:04AM EST B of A Securities Downgrades Intercept Pharmaceuticals to Underperform Benzinga

Jan 11, 2021

08:00AM EST Intercept Appoints Jared M. Freedberg as General Counsel and Secretary GlobeNewswire Inc

Jan 5, 2021

08:39AM EST The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data Benzinga

08:00AM EST Intercept to Present at the 39th Annual J.P. Morgan Healthcare GlobeNewswire Inc

Jan 4, 2021

09:47AM EST Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Filed Against Intercept Pharmaceuticals, Inc. PR Newswire

08:31AM EST Lawsuit Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm PR Newswire

Jan 3, 2021

11:00AM EST ICPT Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Intercept Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 4, 2021 Business Wire

Jan 2, 2021

11:20PM EST Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ICPT PR Newswire

Jan 1, 2021

07:15PM EST ICPT FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, GlobeNewswire Inc

Dec 31, 2020

12:42PM EST ICPT INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds GlobeNewswire Inc

Dec 30, 2020

10:00AM EST ICPT & NVCN Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds GlobeNewswire Inc

08:16AM EST The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data Benzinga

Dec 29, 2020

08:09AM EST The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Benzinga

Dec 28, 2020

12:30PM EST Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

10:18AM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) from September 28, 2019 through October 7, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Intercept Pharmaceuticals, Inc. investors under the federal securities laws. GlobeNewswire Inc

Dec 24, 2020

03:56PM EST ROSEN, A TOP RANKED LAW FIRM, Reminds Intercept Pharmaceuticals, GlobeNewswire Inc

Dec 23, 2020

03:00PM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the Class Period). GlobeNewswire Inc

11:00AM EST ICPT & NVCN Class Actions: Bronstein, Gewirtz & Grossman LLC GlobeNewswire Inc

Dec 22, 2020

05:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

12:47PM EST Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ICPT PR Newswire

11:30AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 21, 2020

07:35PM EST Investors with losses are encouraged to contact the firm before January 4, 2021; click here to submit trade information GlobeNewswire Inc

01:55PM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) from September 28, 2019 through October 7, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Intercept Pharmaceuticals, Inc. investors under the federal securities laws. GlobeNewswire Inc

10:07AM EST Benzinga's Top Upgrades, Downgrades For December 21, 2020 Benzinga

06:49AM EST Jefferies Downgrades Intercept Pharmaceuticals to Hold, Announces $30 Price Target Benzinga

Dec 19, 2020

05:58PM EST Pomerantz Law Firm Announces the Filing of a Class Action against GlobeNewswire Inc

Dec 18, 2020

11:22AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the Class Period). GlobeNewswire Inc

Dec 17, 2020

11:30AM EST Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

Dec 16, 2020

06:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

Dec 15, 2020

11:00AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

10:12AM EST ICPT INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds GlobeNewswire Inc

Dec 14, 2020

01:00PM EST Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming January 4, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Intercept Pharmaceuticals, Inc. (Intercept or the Company) (NASDAQ: ICPT) securities between September 28, 2019 and October 7, 2020 inclusive (the Class Period). GlobeNewswire Inc

Dec 12, 2020

11:52PM EST Pomerantz Law Firm Announces the Filing of a Class Action against GlobeNewswire Inc

Dec 10, 2020

05:28PM EST ROSEN, A GLOBAL AND LEADING LAW FIRM, Reminds Intercept GlobeNewswire Inc

11:15AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

09:47AM EST Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Filed Against Intercept Pharmaceuticals, Inc. PR Newswire

08:04AM EST Intercept Pharmaceuticals Announces Jerry Durso Appointed CEO Effective Jan. 1, 2021 Benzinga

08:00AM EST Jerry Durso Appointed CEO Effective January 1, 2021;Founder, President and CEO Mark Pruzanski to Continue as Board Memberand Advisor GlobeNewswire Inc

Dec 9, 2020

06:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

12:00PM EST Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

09:29AM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) from September 28, 2019 through October 7, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Intercept Pharmaceuticals, Inc. investors under the federal securities laws. GlobeNewswire Inc

Dec 8, 2020

02:00PM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the Class Period). GlobeNewswire Inc

Dec 7, 2020

11:47PM EST Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ICPT PR Newswire

09:13PM EST Pomerantz Law Firm Announces the Filing of a Class Action against GlobeNewswire Inc

Dec 5, 2020

04:02PM EST ICPT INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds GlobeNewswire Inc

Dec 4, 2020

11:15AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

Dec 3, 2020

07:45PM EST ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Reminds Intercept GlobeNewswire Inc

11:30AM EST Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

04:05AM EST Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ICPT PR Newswire

Dec 2, 2020

08:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

12:00PM EST Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming January 4, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Intercept Pharmaceuticals, Inc. (Intercept or the Company) (NASDAQ: ICPT) securities between September 28, 2019 and October 7, 2020 inclusive (the Class Period). GlobeNewswire Inc

Dec 1, 2020

11:00AM EST ICPT & NVCN Class Actions: Bronstein, Gewirtz & Grossman LLC GlobeNewswire Inc

Nov 30, 2020

10:43PM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Nov 26, 2020

12:44PM EST ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, GlobeNewswire Inc

Nov 25, 2020

10:15PM EST Pomerantz Law Firm Announces the Filing of a Class Action against GlobeNewswire Inc

Nov 24, 2020

07:28PM EST Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - ICPT PR Newswire

07:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

07:00AM EST Intercept to Present at the Piper Sandler 32nd Annual Virtual GlobeNewswire Inc

Nov 22, 2020

12:18AM EST Pomerantz Law Firm Announces the Filing of a Class Action against GlobeNewswire Inc

Nov 20, 2020

12:30PM EST Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class PR Newswire

11:00AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

Nov 18, 2020

09:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

11:30AM EST The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class PR Newswire

Nov 17, 2020

11:00AM EST ICPT Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Intercept Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 4, 2021 Business Wire

08:29AM EST Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Nov. 17, 2020: TSLA, BNTX, CTIB, DGNS, ICPT Benzinga

Nov 16, 2020

09:41PM EST Pomerantz Law Firm Announces the Filing of a Class Action against GlobeNewswire Inc

08:09AM EST Intercept Pharmaceuticals Highlights Presentation Of Data At Annual Meeting of the American Association for the Study of Liver Diseases Nov. 13-16 Benzinga

08:00AM EST New Data from the Interim Analysis of REGENERATE Show OCA Improved GlobeNewswire Inc

Nov 14, 2020

02:51PM EST Lawsuit Against Intercept Pharmaceuticals, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - ICPT PR Newswire

Nov 13, 2020

11:00AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

08:00AM EST Investors with losses are encouraged to contact the firm before January 4, 2021; click here to submit trade information GlobeNewswire Inc

Nov 12, 2020

02:12PM EST INTERCEPT PHARMACEUTICALS, INC. CLASS ACTION ALERT: Wolf GlobeNewswire Inc

11:00AM EST ICPT Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC GlobeNewswire Inc

Nov 11, 2020

09:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

11:32AM EST Canaccord Genuity Maintains Hold on Intercept Pharmaceuticals, Raises Price Target to $58 Benzinga

Nov 10, 2020

11:01AM EST Pharmaceuticals, Inc. Investors of Class Action and Lead Plaintiff Deadline: January 4, 2021 PR Newswire

09:36AM EST Credit Suisse Maintains Neutral on Intercept Pharmaceuticals, Lowers Price Target to $42 Benzinga

09:31AM EST Benzinga's Top Upgrades, Downgrades For November 10, 2020 Benzinga

08:16AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

07:39AM EST Raymond James Upgrades Intercept Pharmaceuticals to Outperform, Announces $60 Price Target Benzinga

07:36AM EST Baird Upgrades Intercept Pharmaceuticals to Outperform, Announces $52 Price Target Benzinga

Nov 9, 2020

07:21AM EST Intercept Pharmaceuticals: Q3 Earnings Insights Benzinga

07:04AM EST Intercept Pharmaceuticals Q3 EPS $(2.01) Misses $(1.93) Estimate, Sales $79.50M Beat $78.63M Estimate Benzinga

07:00AM EST Worldwide Ocaliva net sales of $79.5 million in the third quarter 2020, representing 29% growth over the prior year quarter GlobeNewswire Inc

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 7, 2020

04:57PM EST Pomerantz Law Firm Announces the Filing of a Class Action against GlobeNewswire Inc

Nov 6, 2020

04:59PM EST Gainey McKenna & Egleston Announces a Class Action Lawsuit Has GlobeNewswire Inc

03:53PM EST Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Filed Against Intercept Pharmaceuticals, Inc. PR Newswire

08:00AM EST Portnoy Law: Lawsuit Filed On Behalf of Intercept Pharmaceutical, GlobeNewswire Inc

Nov 5, 2020

04:23PM EST Pomerantz Law Firm Announces the Filing of a Class Action against Intercept PR Newswire

Nov 2, 2020

04:00PM EST Intercept to Announce Third Quarter 2020 Financial Results on GlobeNewswire Inc

Oct 29, 2020

10:40PM EDT Scott+Scott Attorneys at Law LLP Announces Investigation into Intercept PR Newswire

08:26AM EDT New PBC And NASH Data To Be Presented At AASLD's The Liver Meeting Digital Experience Nov. 13-16 Benzinga

08:01AM EDT Presentation of long-termefficacy andsafety data of obeticholic acid (OCA)for the treatment of patients with PBC GlobeNewswire Inc

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

Oct 23, 2020

07:00PM EDT Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Intercepts Pharmaceuticals, Inc. (NASDAQ: ICPT) on behalf of Intercept stockholders. Our investigation concerns whether Intercept has violated the federal securities laws and/or engaged in other unlawful business practices. GlobeNewswire Inc

Oct 22, 2020

07:52AM EDT The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat Benzinga

Oct 21, 2020

09:37AM EDT Stocks Trading Near 52-Week Lows In The Pre-Market Session On Wednesday, Oct. 21, 2020: JAGX, HYLN, BUR, ICPT, DCRBU, BXRX, IH, RDI, RBAC Benzinga

08:04AM EDT The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga

Oct 20, 2020

08:17AM EDT The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger Benzinga

Oct 14, 2020

08:38PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of PR Newswire

Sep 3, 2020

08:00AM EDT Intercept to Present at September Investor Conference GlobeNewswire Inc

Sep 1, 2020

11:14AM EDT Intercept Pharmaceuticals Discloses In 8K Co Will Reduce Workforce By Around 25%, Or 170 Employes; Will Incur Charges Of ~$18M Benzinga

Aug 27, 2020

08:07AM EDT Intercept Pharmaceuticals Reports That New Data From Interim Analysis Of REGENERATE Show That OCA Helped Patients With Liver Fibrosis Due To NASH Achieve Sustained Improvement In Noninvasive Markers Of Fibrosis Over Two Years Of Treatment Benzinga

08:00AM EDT New Data from the Interim Analysis of REGENERATE Show that OCA GlobeNewswire Inc

Aug 21, 2020

08:01AM EDT Intercept To Present New NASH And PBC Data At The Digital International Liver Congress 2020 Benzinga

08:00AM EDT New analyses of the interim analysis data from the Phase 3 REGENERATE study describe the benefit of obeticholic acid (OCA) on noninvasive measures of liver fibrosisin NASH patients on treatment for at least 24 months GlobeNewswire Inc

Aug 10, 2020

09:12AM EDT Intercept Pharmaceuticals Sees FY2020 Sales $300.000M-320.000M vs $288.07M Est Benzinga

07:26AM EDT Recap: Intercept Pharmaceuticals Q2 Earnings Benzinga

07:09AM EDT Intercept Pharmaceuticals Q2 EPS $(1.92) Beats $(2.92) Estimate, Sales $77.25M Beat $72.15M Estimate Benzinga

07:00AM EDT Worldwide Ocaliva net sales of $77.2 million in the second quarter 2020, representing 17% growth over the prior year quarter GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 3, 2020

08:08AM EDT Intercept to Announce Second Quarter 2020 Financial Results on GlobeNewswire Inc

Jul 15, 2020

05:07PM EDT Intercept Pharma 8-K Shows Co. Received Paragraph IV Certification Notice From Apotex Indicated Apotex Submitted To FDA Abbreviated New Drug Application Seeking Approval To Manufacture, Sell Generic Version Of Co.'s Ocaliva Benzinga

Share